See today's BioWorld Asia
To read the full story, subscribe or sign in.

After Zika cure, Tychan accelerates monoclonal antibody for yellow fever

Dec. 12, 2018
By David Ho
HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development.
BioWorld Asia